Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
What to Know About Biosimilar for Stelara That Can Treat Psoriasis
The FDA approved Wezlana, the first biosimilar to Stelara, a leading psoriasis drug, following Amgen's successful trials and a legal settlement with Johnson & Johnson. Biosimilars, rigorously reviewed for safety and efficacy, offer cost-effective treatment options for inflammatory diseases, despite their complex production process.
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT Combined with Lazertinib Significantly Improves Progression-Free Survival in EGFR-Mutated NSCLC Patients
The MARIPOSA study revealed RYBREVANT® combined with lazertinib significantly improves progression-free survival (PFS) in EGFR-mutated NSCLC patients compared to osimertinib, with a 30% reduction in disease progression or death risk. Results showed a favorable overall survival trend and consistent benefits across patient subgroups, including those with brain metastases.
Related Clinical Trials:
J&J cancer drug combo beats Tagrisso in closely watched trial
Johnson & Johnson's drug combo, Rybrevant and lazertinib, outperformed AstraZeneca's Tagrisso in a late-stage trial for EGFR-mutated non-small cell lung cancer, showing longer progression-free survival. J&J plans to present detailed results at a future medical conference, aiming to compete in the lung cancer drug market.
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Demonstrating Significant Improvement in Progression-Free Survival for EGFR-Mutated NSCLC Patients
The Phase 3 MARIPOSA-2 study demonstrated significant improvement in progression-free survival for patients with EGFR-mutated NSCLC using RYBREVANT® with and without lazertinib plus chemotherapy, compared to chemotherapy alone. This marks a potential shift in treatment paradigms for post-osimertinib NSCLC patients.
Related Clinical Trials:
10 Dementia Medications that are Approved or in Clinical Trials
The article highlights 10 dementia medications approved or in clinical trials, emphasizing advancements in medicine and the impact of Covid-19 on life expectancy. It discusses the increasing prevalence of dementia, the role of major pharmaceutical companies in research, and the focus on treating symptoms rather than curing dementia.
Immix Biopharma's Subsidiary Reports Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Nexcella Inc, a subsidiary of Immix Biopharma Inc, reported 100% overall response rate in AL Amyloidosis patients treated with NXC-201, a BCMA-targeted CAR-T cell therapy, in a Phase 1b/2a study. The therapy showed a 63% complete response rate, 75% organ response rate, and no grade 4 CRS events, indicating potential efficacy and tolerability for advanced AL amyloidosis.
How Can MedTech Leverage Technological Innovation
Medtech companies face challenges in global expansion, requiring strategic precision and technological innovation. Industry leaders emphasize the importance of market understanding, regulatory compliance, and leveraging AI in healthcare. Successful internationalization demands clear goals, product differentiation, and meticulous planning, with a focus on localization and strategic partnerships.
Effects of teclistamab and talquetamab on soluble BCMA in multiple myeloma therapy
BCMA is a key target in multiple myeloma (MM) therapy, with sBCMA levels potentially affecting treatment efficacy. Studies on teclistamab and talquetamab show sBCMA reduction correlates with treatment response, suggesting its utility as a response marker. Baseline sBCMA levels also correlate with tumor burden, indicating its role in MM progression and therapy monitoring.
At 9.5% CAGR, Cardiac Cath Lab Market Size is likely to Hit $87 Billion by 2029
The global Cardiac Cath Lab Market is projected to hit $87 billion by 2029, growing at a 9.5% CAGR from 2022-2029. Growth is driven by advancements in cardiac catheterization techniques, equipment, and the rising prevalence of cardiac conditions. Despite risks like stroke and renal failure, new technologies and improved expertise are reducing complications, enhancing patient outcomes, and fostering market expansion.
New Sanofi and GSK vaccine demonstrates strong protection against severe Covid-19 in clinical trials
Sanofi and GSK's Vidprevtyn, a protein subunit Covid-19 vaccine, shows promising phase 3 trial results, with 58% efficacy against symptoms, 75% against moderate/severe disease, and 100% against severe disease. It's effective as a booster, increasing antibodies 18-30 fold. Plans to seek US and EU authorization, with 100 million doses already produced.
© Copyright 2025. All Rights Reserved by MedPath